The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same (New York Times).
Summary: MAPS is featured in an article on the front page of today's edition of The New York Times!
Topical PTSD Drug Poised for Human Trials.
In a press release issued on February 15, Psycheceutical Bioscience (BWVI), in partnership with iNGENū, a contract research organization in the cannabinoid...
The FDA Cracks Down On Stem Cell Therapy.
Due to a somewhat unexpected crackdown on stem cell treatment centers a couple of weeks ago - we have decided to hold...
Ehave (EHVVF) Looks to Power the Psychedelics Revolution
Mental illness will cost the global economy $16 trillion by 2030 due to early-onset and lost productivity, with an estimated 12 billion working days...
Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs
Cybin (CLXPF CYBN) Banks $30 Million Overnight.
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares.
LIVE QUOTE
Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
Not wanting to be caught...
Psychedelic Primer Guide. (Psychedelic Medicine Association)
The Psychedelic Medicine Association (PMA) is a society of physicians, therapists, and health care professionals looking to advance their education on the...
Revive Therapeutics (RVVTF) Advancing MDMA Thermal Patch.
Two News Reports Related to Revives Upcoming Microneedle Patch Technology
While we are still laser focused on Revive...
Video: New Topical Drug Delivery System, NeuroDirect™
Must Watch Video. Topical Application to Improve Delivery of FDA-Approved Drugs.
https://youtu.be/2CGT7P9QEvo
Can...
Latest article
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
